Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
With year end results narrowing the loss to (.18) for the quarter, and (.99) for the year, EXAS is on the road to profitability. Projections for 2018 are that revenue should grow from $266 million to $420 ~ $430 million for the year. Facilities are being build to service this significant growth in Cologuard tests. If the projections stay on course, the volume of tests will approach one million for the year, which is still significantly less than what the market share could be.

And that's in the United States alone.

Management seems to have a handle on growing this portion of the business. I'm looking forward to sustained growth in sales for several more years. It will be interesting to see if R&D will come up with complimentary products or an enhanced version of this test that utilizes blood draw versus stool sample.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.